Peer-reviewed veterinary case report
How well Simparica Trio and NexGard Spectra stop paralysis ticks
By Packianathan, Raj et al.·Published in Parasites & vectors·2020·Zoetis Australia Research and Manufacturing Pty Ltd, Australia·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Efficacy of combination products containing sarolaner, moxidectin and pyrantel (Simparica Trio™) or afoxolaner and milbemycin (NexGard Spectra) against induced infestations of Ixodes holocyclus in dogs.
- Species:
- dog
Plain-English summary
A group of 24 foxhounds was tested for protection against the Australian paralysis tick, which can cause serious health issues in dogs. The dogs were treated with either Simparica Trio or NexGard Spectra, both of which are combination medications designed to kill ticks. Both treatments were found to be highly effective, with Simparica Trio eliminating 99.6% of ticks and NexGard Spectra achieving 100% effectiveness within 48 hours. Neither treatment caused any side effects, and both provided strong protection against tick infestations for up to 35 days.
People also search for: dog tick prevention · Simparica Trio for ticks · NexGard Spectra effectiveness · Australian paralysis tick treatment · foxhound tick protection
Abstract
BACKGROUND: The Australian paralysis tick, Ixodes holocyclus, causes tick paralysis in dogs and cats in the eastern coastal regions of Australia. Prevention is the best option to protect dogs against this potentially fatal disease and sarolaner provides rapid and sustained efficacy against I. holocyclus. In this laboratory study, the efficacy of two combination endectocides containing sarolaner + moxidectin + pyrantel (Simparica Trio™) and afoxolaner + milbemycin (NexGard Spectra) was evaluated against an artificial infestation of I. holocyclus. METHODS: Twenty-four (n =24) foxhounds were randomly allocated to three treatment groups and artificially infested with 30 adult female viable ticks on Days - 1, 7, 14, 21, 28 and 35. On Day 0, dogs in each treatment group were treated with either Drontal(control group), Simparica Trio™ at the label dose to provide minimum doses of sarolaner (1.2 mg/kg), moxidectin (24 µg/kg) and pyrantel (5 mg/kg) or NexGard Spectrato provide minimum doses of afoxolaner (2.5 mg/kg) and milbemycin (0.5 mg/kg). Live tick counts were performed at 48 and 72 hours after treatment and after each re-infestation on Days 7, 14, 21, 28 and 35. Efficacy was determined at each time point relative to counts for control dogs based on geometric means. RESULTS: Against an existing infestation, efficacy of both Simparica Trio™ and NexGard Spectrawas 99.6% and 100% at 48 and 72 h time points, respectively (P = 1.000). Against subsequent weekly infestations, treatment with Simparica Trio™ and NexGard Spectraresulted in efficacy of ≥ 97.7% and ≥ 95.5% (P ≥ 0.0911), respectively at the 48 h time point and at the 72 h time point, Simparica Trio™ and NexGard Spectraresulted in efficacy of ≥ 99.0% and ≥ 98.4% (P ≥ 0.0511), respectively. There were no treatment-related adverse events in the study. CONCLUSIONS: Single doses of Simparica Trio™ and NexGard Spectrawere highly efficacious and provided comparable efficacy against the Australian paralysis tick, I. holocyclus for up to 35 days.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32891172/